MediWound 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 revenue was $3.6 million, compared with $5.4 million in the third quarter of 2025, primarily reflecting lower U.S. government development-services revenue.
- Gross profit was $1 million, with a gross margin of 28.5%, compared with $0.9 million and 16.5% in the prior-year period; the improvement primarily reflected a higher contribution from royalty revenue.
- Research and development expenses were $6.2 million, compared with $3.5 million, primarily reflecting increased investment in the EscharEx Phase 3 VALUE trial; SG&A expenses were $3.4 million, compared with $4 million.
- Operating loss was $8.5 million, compared with $6.5 million, and net loss was $6 million, or $0.47 per share, compared with $2.7 million, or $0.24 per share; adjusted EBITDA loss was $7.4 million, compared with $5.4 million.
- For the first 9 months of 2026, revenue was $8.1 million, compared with $15.1 million in the first 9 months of 2025, primarily due to lower U.S. government development-services revenue.
- For the first 9 months of 2026, research and development expenses were $17.3 million, compared with $9.8 million; SG&A expenses were $10.8 million, compared with $10.6 million; operating loss was $26 million, compared with $17.5 million.
- Net loss for the first 9 months of 2026 was $16.3 million, or $1.27 per share, compared with $16.7 million, or $1.53 per share; adjusted EBITDA loss was $22.7 million, compared with $13.8 million.
- As of September 30th, 2026, MediWound had $28.4 million in cash, cash equivalents, and deposits, and cash burn during the first 9 months of 2026 totaled $28.3 million.
- Warrant exercises generated $2 million during the first 9 months, with an additional $1.1 million received after quarter-end; a November 2026 underwritten public offering, including full exercise of the right-hand shoe option, generated gross proceeds of $17.25 million.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and welcome to MediWound's third quarter 2026 earnings call. As all participants will be in listen-only mode, should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note, this event is being recorded. At this time, I would like to turn the conference over to Gaia Vasiliver-Shamis of LifeSci Advisors.
Please go ahead. Thank you, Sagar, and welcome, everyone.
Earlier today, before the market opened, MediWound issued a press release announcing financial results for the third quarter ended September 30, 2026. I would ask you to review the full text of our forward-looking statements within this morning press release. Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session, relating to MediWound's expected future performance, future business prospects, or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. These statements may involve risk and uncertainties that could cause actual results to differ materially from expectations and are described more fully in our filings with the SEC.
In addition, all forward-looking statements represent our view only as of today, and MediWound assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events, or otherwise. This conference call is the property of MediWound, and any recording or rebroadcast is expressly prohibited without the written consent of MediWound. With us today are Ofer Gonen, Chief Executive Officer of MediWound, Hani Luxenburg, Chief Financial Officer, and Barry Wolfenson, Executive Vice President of Strategy and Corporate Development. Following our prepared remarks, we will open the call for Q&A. Now, I would like to turn the call over to Ofer Gonen, Chief Executive Officer of MediWound.
Ofer? Thank you, Gaia, and good morning, everyone.
During the third quarter, we advanced EscharEx development, supported NexoBrid's commercial growth and government program, and continued preparing our expanded manufacturing facility to meet future demand. Let me start with an update on EscharEx. The global phase III VALUE trial in venous leg ulcers remains our top priority. Enrollment continues, and we remain on track to complete the pre-specified interim sample size reassessment in the enrollment by the end of the first quarter of 2027. The current enrollment target is 216 patients across approximately 40 sites in the United States, Europe, and Israel. During the quarter, the independent Data and Safety Monitoring Board completed its pre-specified periodic review of the VALUE trial, identified no safety concern, and recommended that the trial continues as planned without modifications. The next DSMB meeting is scheduled for early January 2027.
The following meeting is expected at the end of the first quarter of 2027, at which the DSMB will also conduct the interim sample size reassessment. Beyond venous leg ulcers, we continue to advance towards clinical trials in diabetic foot ulcers and pressure ulcers. The diabetic foot ulcer program has received grant funding from the European Innovation Council and is supported by strategic collaborations, while work on pressure ulcer is investigator-initiated. Once final results from the VALUE trial are available, we plan to discuss the development pathway for additional chronic wound indications with the FDA. Turning to NexoBrid. The U.S. commercial trajectory continues to strengthen. Vericel reported NexoBrid's strongest quarter since launch, with its highest quarterly revenue to date, driven by the highest number of ordering burn centers and hospital orders ever. More new centers ordered NexoBrid in the first nine months of 2026 than in all 2025.
More than 80 centers have placed orders to date, with approximately 70 placing repeat orders. Government procurement under Vericel's BARDA contract began in the third quarter, and as Vericel indicated, is expected to continue through the fourth quarter of 2026 and the first quarter of 2027. We continue to collaborate with Vericel in advancing two NexoBrid development programs under our master service agreement, indication expansion to acute trauma injuries associated with thermal burns, and development of a new stable formulation. Both programs are covered by the contract between Vericel and BARDA. Separately, the Department of War awarded MediWound an additional $3.3 million in non-dilutive funding to advance the room temperature stable formulation of NexoBrid as a non-surgical debridement solution for battlefield burn care. This brings the program's total budget to $21.8 million and is intended to support the development through submission of an IND application.
Together, these programs are intended to broaden NexoBrid's potential applications in civilian and military burn care. Beyond the United States, demand for NexoBrid extends across Europe, Japan, and other markets. However, global demand currently exceeds our manufacturing capacity, limiting our ability to fully meet the needs of these markets. Expanding our capacity is therefore a key priority for us. Let me provide some context on our manufacturing operations, starting with our current NexoBrid facility. The facility successfully completed routine GMP inspections by the FDA and the Israeli Ministry of Health, with the ministry also conducting its inspection on behalf of the EMA. The facility's GMP certification is valid now for an additional two years. To address the capacity constraints and support the future demand, we are advancing our expanded NexoBrid manufacturing facility.
We are implementing the modification recommended during the previously reported EMA pre-audit and expect to complete this work in the fourth quarter of 2026 as planned. Commercial supply from the expanded facility remains subject to regulatory approval and is expected in the second half of 2027. With that, I will turn the call over to Hani.
Thank you, Ofer, and good morning, everyone. Before I walk through the numbers, let me put our result in context. Our revenue is heavily weighted toward development services for U.S. government programs. Product sales, meanwhile, are constrained by supply rather than demand. We are selling every unit we can manufacture. On the expense side, our main investment is in R&D, mainly the EscharEx phase III VALUE trial. We expect spending on that trial to decline substantially as it reaches completion. Now turning to our financial result for the third quarter of 2026. Revenue for the quarter was $3.6 million, compared with $5.4 million in the third quarter of 2025. The decrease was primarily attributable to lower revenue from development services related to the U.S. government. Gross profit was $1 million, representing a gross margin of 28.5%, compared with gross profit of $0.9 million or 16.5% in the prior year period.
The margin improvement primarily reflected a higher contribution from royalty revenue, which carries a higher gross margin. Research and development expenses were $6.2 million compared with $3.5 million in the third quarter of 2025, primarily reflecting increased investment in the EscharEx phase III VALUE trial. SG&A expenses totaled $3.4 million compared with $4 million in the same period last year. The decrease primarily reflected lower marketing expenses. Operating loss was $8.5 million compared with $6.5 million in the third quarter of 2025. Net loss was $6 million or $0.47 per share, compared with a net loss of $2.7 million or $0.24 per share in the prior year period. The year-over-year change primarily reflected lower non-cash financial income from revaluation of warrants. Adjusted EBITDA loss was $7.4 million compared with a loss of $5.4 million in the third quarter of 2025.
Turning to our result for the first nine months. Revenue for the first nine months of 2026 was $8.1 million compared with $15.1 million in the first nine months of 2025, primarily attributable to lower revenue from development services related to U.S. government. Gross profit of $3 million or 19.7% in the prior year period. The margin improvement primarily reflected a higher contribution from royalty revenue. Research and development expenses were $17.3 million compared with $9.8 million in the first nine months of 2025, primarily reflecting increased investment in the EscharEx phase III VALUE trial. SG&A expenses totaled $10.8 million compared with $10.6 million in the same period last year. Operating loss was $26 million compared with $17.5 million in the first nine months of 2025.
Net loss was $16.3 million or $1.27 per share compared with a net loss of $16.7 million or $1.53 per share in the prior year period. The change primarily reflected non-cash warrant revaluation income of $10.3 million in 2026 compared with $1.8 million in 2025. Adjusted EBITDA loss was $22.7 million compared with a loss of $13.8 million in the first nine months of 2025. Turning to our balance sheet. As of September 30, 2026, we had $28.4 million in cash equivalents, and deposits, compared with $53.6 million at year-end 2025. Cash burn during the first nine months of 2026 totaled $28.3 million. Warrant exercises generated $2 million during the first nine months, and we received an additional $1.1 million after quarter end.
Those exercising warrants included all board members who held warrants, the company's founder, and our CEO, each of whom also agreed to lock-up restrictions. In addition, in November 2026, we closed an underwritten public offering, including the full exercise and overallotment option for gross proceeds of $17.25 million. This concludes my review of our financial results, Ofer.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
